ARCA biopharma's EBIT per Share for the
three
months ended in Mar. 2024 was $-0.17.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.55.
During the past 3 years, the average EBIT per Share Growth Rate was 37.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 45.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 42.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ARCA biopharma's EBIT per Share or its related term are showing as below:
ABIO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -39.4 Med: 41.15 Max: 69.3
Current: 37.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of ARCA biopharma was 69.30% per year. The lowest was -39.40% per year. And the median was 41.15% per year.
ABIO's 3-Year EBIT Growth Rate is ranked better than 86.37% of 1306
companies
in the Biotechnology industry
Industry Median: 3.5
vs ABIO: 37.50
ARCA biopharma's EBIT for the
three
months ended in Mar. 2024 was $-2.48 Mil.
ARCA biopharma EBIT per Share Historical Data
The historical data trend for ARCA biopharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCA biopharma (NAS:ABIO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ARCA biopharma EBIT per Share Related Terms
Thank you for viewing the detailed overview of ARCA biopharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
ARCA biopharma (ARCA biopharma) Business Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABIO has been successfully added to your 